SEARCH

SEARCH BY CITATION

References

  • 1
    Roux PP,Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 3204.
  • 2
    Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005; 5: 9218.
  • 3
    Bulavin DV,Fornace AJ. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004; 92: 95118.
  • 4
    Olson JM,Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004; 10: 1259.
  • 5
    Brancho D,Tanaka N,Jaeschke A,Ventura JJ,Kelkar N,Tanaka Y,Kyuuma M,Takeshita T,Flavell RA,Davis RJ. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003; 17: 196978.
  • 6
    Kharbanda S,Ren R,Pandey P,Shafman TD,Feller SM,Weichselbaum RR,Kufe DW. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995; 376: 7858.
  • 7
    Baskaran R,Wood LD,Whitaker LL,Canman CE,Morgan SE,Xu Y,Barlow C,Baltimore D,WynshawBoris A,Kastan MB,Wang JYJ. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 5169.
  • 8
    Kharbanda S,Pandey P,Ren R,Mayer B,Zon L,Kufe D. c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-β-D-arabinofuranosylcytosine. J Biol Chem 1995; 270: 3027881.
  • 9
    Sanchez-Arevalo LV,Aceves Luquero CI,Alvarez-Vallina L,Tipping AJ,Viniegra JG,Hernandez LJ,Parada CC,Galan Moya EM,Gayoso CJ,Melo JV,Cajal S,Sanchez-Prieto R. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J 2005; 387 (Part 1): 2318.
  • 10
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 726579.
  • 11
    Gong JG,Costanzo A,Yang HQ,Melino G,Kaelin WG,Jr,Levrero M,Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 8069.
  • 12
    Truong T,Sun G,Doorly M,Wang JY,Schwartz MA. Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci USA 2003; 100: 102816.
  • 13
    Tsai KK,Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 2003; 63: 341824.
  • 14
    Losa JH,Cobo CP,Viniegra JG,Lobo VJSA,Cajal SRY,Sanchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003; 22: 39984006.
  • 15
    Potapova O,Haghighi A,Bost F,Liu C,Birrer MJ,Gjerset R,Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997; 272: 140414.
  • 16
    Sanchez-Perez I,Murguia JR,Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998; 16: 53340.
  • 17
    Sanchez-Prieto R,Rojas JM,Taya Y,Gutkind JS. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 2000; 60: 246472.
  • 18
    Cong F,Goff SP. C-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. Proc Natl Acad Sci USA 1999; 96: 1381924.
  • 19
    Kharbanda S,Pandey P,Yamauchi T,Kumar S,Kaneki M,Kumar V,Bharti A,Yuan ZM,Ghanem L,Rana A,Weichselbaum R,Johnson G, et al. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol 2000; 20: 497989.
  • 20
    Nehme A,Baskaran R,Aebi S,Fink D,Nebel S,Cenni B,Wang JY,Howell SB,Christen RD. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and-deficient cells exposed to cisplatin. Cancer Res 1997; 57: 32537.
  • 21
    Pandey P,Raingeaud J,Kaneki M,Weichselbaum R,Davis RJ,Kufe D,Kharbanda S. Activation of p38 mitogen-activated protein kinas by c-Abl-dependent and -independent mechanisms. J Biol Chem 1996; 271: 237759.
  • 22
    Agami R,Blandino G,Oren M,Shaul Y Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 1999; 399: 80913.
  • 23
    Yuan ZM,Shioya H,Ishiko T,Sun X,Gu J,Huang YY,Lu H,Kharbanda S,Weichselbaum R,Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 81417.
  • 24
    Sionov RV,Coen S,Goldberg Z,Berger M,Bercovich B,Ben-Neriah Y,Ciechanover A,Haupt Y. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 2001; 21: 586978.
  • 25
    Buchdunger E,Zimmermann J,Mett H,Meyer T,Muller M,Druker BJ,Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 1004.
  • 26
    Corbin AS,Buchdunger E,Pascal F,Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 322149.
  • 27
    Druker BJ,Tamura S,Buchdunger E,Ohno S,Segal GM,Fanning S,Zimmermann J,Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 5616.
  • 28
    Druker BJ. ST1571 (Gleevec (TM)) as a paradigm for cancer therapy. Trends Mol Med 2002; 8: S14S18.
  • 29
    Fukuhara S,Marinissen MJ,Chiariello M,Gutkind JS. Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves Gα q and Gα 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras AND Rho-independent pathway. J Biol Chem 2000; 275: 217306.
  • 30
    Sanchez-Prieto R,Sanchez-Arevalo VJ,Servitja JM,Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 2002; 21: 9749.
  • 31
    Brozovic A,Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251: 116.
  • 32
    Choi SY,Kim MJ,Kang CM,Bae S,Cho CK,Soh JW,Kim JH,Kang S,Chung HY,Lee YS,Lee SJ. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J Biol Chem 2006; 281: 704959.
  • 33
    Buschbeck M,Hofbauer S,Croce LD,Keri G,Ullrich A. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 2005; 6: 639.
  • 34
    Johnson FM,Krug LM,Tran HT,Shoaf S,Prieto VG,Tamboli P,Peeples B,Patel J,Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006; 106: 36674.
  • 35
    Goldberg Z,Vogt Sionov R,Berger M,Zwang Y,Perets R,Van Etten RA,Oren M,Taya Y,Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 2002; 21: 371527.
  • 36
    Chen X,Zhang J,Lee J,Lin PS,Ford JM,Zheng N,Zhou P. A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mol Cell 2006; 22: 48999.
  • 37
    Kaplan KB,Swedlow JR,Morgan DO,Varmus HE. c-Src enhances the spreading of src−/− fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 1995; 9: 150517.
  • 38
    Schwartzberg PL,Xing L,Hoffmann O,Lowell CA,Garrett L,Boyce BF,Varmus HE. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src−/− mutant mice. Genes Dev 1997; 11: 283544.
  • 39
    Yu CR,Krystal G,Varticovksi L,McKinstry R,Rahmani M,Dent P,Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002; 62: 18899.
  • 40
    Parmar S,Katsoulidis E,Verma A,Li Y,Sassano A,Lal L,Majchrzak B,Ravandi F,Tallman MS,Fish EN,Platanias LC. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279: 2534552.